Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 221

Sort by

Sort Order Select

Journal Articles

Prognostic impact of diagnosis-to-treatment interval in follicular lymphoma patients treated with immunochemotherapy: Evidence from an international cohort with independent validation

Blood (2025) 146 (Supplement 1): 3601.

https://doi.org/10.1182/blood-2025-3601

Published: 2025

Journal Articles

Prognostic impact of Mantle Cell Lymphoma frontline induction response assessments in the ECOG-ACRIN E1411 study of bendamustine-rituximab +/- bortezomib and maintenance with rituximab +/- lenalidomide

Christine Ryan, Victoria Wang, Mitchell Smith, Brian Till, Samir Parekh, David Yang, Lale Kostakoglu, Nizar Abdel Samad, Opeyemi Jegede, Richard Little, Jonathan Friedberg, John Leonard, Brad Kahl, Peter Martin

Blood (2025) 146 (Supplement 1): 3581.

https://doi.org/10.1182/blood-2025-3581

Published: 2025

Journal Articles

Survival differences in metropolitan versus nonmetropolitan/rural counties in the US: An analysis according to rural-urban continuum codes (RUCC) in the lymphoma epidemiology of outcomes (LEO) study cohort

Blood (2025) 146 (Supplement 1): 6324.

https://doi.org/10.1182/blood-2025-6324

Published: 2025

Journal Articles

Patterns of care and outcomes in patients with large B-cell lymphoma not treated with full-dose anthracycline regimens: Outcome analysis from the lymphoma epidemiology of outcomes (LEO) prospective cohort study

Blood (2025) 146 (Supplement 1): 6312.

https://doi.org/10.1182/blood-2025-6312

Published: 2025

Journal Articles

Zanubrutinib and venetoclax as initial therapy for CLL/SLL with obinutuzumab triplet consolidation in patients with detectable minimal residual disease (BruVenG).

John Allan, Erin Mulvey, Daniel Helbig, Nikita Malakhov, Zhengming Chen, Brittany Hobbie, Sarah Nazir, Jerrod White, Zahra Grant, Jane Matejka, Simone Morris, Liming Bao, Peter Martin, Richard Furman

Blood (2025) 146 (Supplement 1): 3886.

https://doi.org/10.1182/blood-2025-3886

Published: 2025

Journal Articles

Outcomes of T-cell/histocyte-rich large B-cell lymphoma (THRLBCL): An international LEO/MER and NiHiL collaborative study

Blood (2025) 146 (Supplement 1): 898.

https://doi.org/10.1182/blood-2025-898

Published: 2025

Journal Articles

Survival difference among patients with large B-cell lymphoma (LBCL) based on first-line clinical trial participation: A multi-institutional analysis of 8 academic institutions in the lymphoma epidemiology of outcomes (LEO) cohort

Chijioke Nze, Clark Andersen, Matthew Maurer, Melissa Larson, Jean Koff, Jonathon Cohen, Thomas Habermann, Jonathan Friedberg, Izidore S. Lossos, Peter Martin, Brad Kahl, David Jaye, Andrew Feldman, Carrie Thompson, James Cerhan, Christopher Flowers

Blood (2025) 146 (Supplement 1): 895.

https://doi.org/10.1182/blood-2025-895

Published: 2025

Journal Articles

Shorter diagnosis to treatment interval is associated with poor prognosis in patients with peripheral T-cell lymphoma: Analysis from the LEO and MER cohorts

Blood (2025) 146 (Supplement 1): 5439.

https://doi.org/10.1182/blood-2025-5439

Published: 2025

Journal Articles

Optimizing risk stratification in patients aged 80+ years with large B-cell lymphoma: Comparison of prognostic indices in three pooled international cohorts

Blood (2025) 146 (Supplement 1): 786.

https://doi.org/10.1182/blood-2025-786

Published: 2025

Journal Articles

FLP-R: A clinical prediction model for follicular lymphoma Prognosis in the Relapsed/refractory setting

Blood (2025) 146 (Supplement 1): 5354.

https://doi.org/10.1182/blood-2025-5354

Published: 2025

Journal Articles

Multi-center real world analysis of treatment outcomes of non-COVALENT btki, pirtobrutinib, in patients with COVALENT btki relapsed/refracdtory Mantle Cell Lymphoma

Blood (2025) 146 (Supplement 1): 5351.

https://doi.org/10.1182/blood-2025-5351

Published: 2025

Journal Articles

Treatment patterns in patients aged 80+ years with LBCL: Propensity score analysis reveals comparable outcomes between R-CHOP and R-mini-CHOP

Blood (2025) 146 (Supplement 1): 5448.

https://doi.org/10.1182/blood-2025-5448

Published: 2025

Journal Articles

Predictive performance of the LEO comorbidity index in patients aged 80+ years with large B-cell lymphoma

Blood (2025) 146 (Supplement 1): 2741.

https://doi.org/10.1182/blood-2025-2741

Published: 2025

Journal Articles

Age-stratified prognostic performance of patient- vs disease-related IPI factors in large B-cell lymphoma

Blood (2025) 146 (Supplement 1): 4516.

https://doi.org/10.1182/blood-2025-4516

Published: 2025

Journal Articles

FLIPI24 as a prognostic model in marginal zone lymphoma: Results from an international multi-cohort analysis

Blood (2025) 146 (Supplement 1): 1826.

https://doi.org/10.1182/blood-2025-1826

Published: 2025

Journal Articles

The use and safety of peripheral intravenous catheters (PIV) vs central venous catheters (CVC) for lymphoma patients receiving frontline anthracycline-based chemotherapy: A large multicenter real-world analysis (RWA)

Blood (2025) 146 (Supplement 1): 518.

https://doi.org/10.1182/blood-2025-518

Published: 2025

Journal Articles

A phase 1b trial of the EZH2 inhibitor tazemetostat combined with CAR T cell therapy in B cell lymphomas

Samuel Yamshon, Caitlin Gribbin, Yusuke Isshiki, Ioannis Karagiannidis, Sunjae Lee, Jizhi Yan, Gwynne Ozkan, Anna Alperovich, Barbara Ma, Christopher Hackett, Mateo Mejia-Saldarriaga, Daniel Choi, Selina Chen-Kiang, John Leonard, Ari Melnick, Juliet Barker, Giorgio Inghirami, Wendy Béguelin, Peter Martin

Blood (2025) 146 (Supplement 1): 1011.

https://doi.org/10.1182/blood-2025-1011

Published: 2025

Journal Articles

Characterization of two genetically distinct subtypes of C5 diffuse large B-cell lymphoma (DLBCL)

Meng Wang, Joji Shimono, Shashwat Sahay, Chidimma Agatha Akpa, Christina Schniederjohann, Julia Richter, Peter-Martin Bruch, Ulrich Dührsen, Michael Hummel, Andreas Rosenwald, Wolfram Klapper, Sascha Dietrich, Ulrich Keller, Björn Chapuy

Blood (2025) 146 (Supplement 1): 50.

https://doi.org/10.1182/blood-2025-50

Published: 2025

Journal Articles

Real-world impact of differences in the WHO and ICC classifications of non-Hodgkin lymphoma: a LEO cohort study analysis

Blood (2024) 144 (19): 2063–2066.

https://doi.org/10.1182/blood.2024025681

Published: 2024

Includes: Supplemental data

Journal Articles

Frontline R-CHOP and BR Have Similar Outcomes By SUV max in Follicular Lymphoma

Blood (2024) 144 (Supplement 1): 3007.

https://doi.org/10.1182/blood-2024-202088

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Prognostic impact of diagnosis-to-treatment interval in follicular lymphoma patients treated with immunochemotherapy: Evidence from an international cohort with independent validation

Prognostic impact of Mantle Cell Lymphoma frontline induction response assessments in the ECOG-ACRIN E1411 study of bendamustine-rituximab +/- bortezomib and maintenance with rituximab +/- lenalidomide

Survival differences in metropolitan versus nonmetropolitan/rural counties in the US: An analysis according to rural-urban continuum codes (RUCC) in the lymphoma epidemiology of outcomes (LEO) study cohort

Patterns of care and outcomes in patients with large B-cell lymphoma not treated with full-dose anthracycline regimens: Outcome analysis from the lymphoma epidemiology of outcomes (LEO) prospective cohort study

Zanubrutinib and venetoclax as initial therapy for CLL/SLL with obinutuzumab triplet consolidation in patients with detectable minimal residual disease (BruVenG).

Outcomes of T-cell/histocyte-rich large B-cell lymphoma (THRLBCL): An international LEO/MER and NiHiL collaborative study

Survival difference among patients with large B-cell lymphoma (LBCL) based on first-line clinical trial participation: A multi-institutional analysis of 8 academic institutions in the lymphoma epidemiology of outcomes (LEO) cohort

Shorter diagnosis to treatment interval is associated with poor prognosis in patients with peripheral T-cell lymphoma: Analysis from the LEO and MER cohorts

Optimizing risk stratification in patients aged 80+ years with large B-cell lymphoma: Comparison of prognostic indices in three pooled international cohorts

FLP-R: A clinical prediction model for follicular lymphoma Prognosis in the Relapsed/refractory setting

Multi-center real world analysis of treatment outcomes of non-COVALENT btki, pirtobrutinib, in patients with COVALENT btki relapsed/refracdtory Mantle Cell Lymphoma

Treatment patterns in patients aged 80+ years with LBCL: Propensity score analysis reveals comparable outcomes between R-CHOP and R-mini-CHOP

Predictive performance of the LEO comorbidity index in patients aged 80+ years with large B-cell lymphoma

Age-stratified prognostic performance of patient- vs disease-related IPI factors in large B-cell lymphoma

FLIPI24 as a prognostic model in marginal zone lymphoma: Results from an international multi-cohort analysis

The use and safety of peripheral intravenous catheters (PIV) vs central venous catheters (CVC) for lymphoma patients receiving frontline anthracycline-based chemotherapy: A large multicenter real-world analysis (RWA)

A phase 1b trial of the EZH2 inhibitor tazemetostat combined with CAR T cell therapy in B cell lymphomas

Characterization of two genetically distinct subtypes of C5 diffuse large B-cell lymphoma (DLBCL)

Real-world impact of differences in the WHO and ICC classifications of non-Hodgkin lymphoma: a LEO cohort study analysis

Frontline R-CHOP and BR Have Similar Outcomes By SUV max in Follicular Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only